ClinicalTrials.gg
RecruitingNCT07392450Updated Aug 14, 2026

A Study of TAK-755 in Adults With Acute Ischemic Stroke

A Phase 2 interventional study of TAK-755 and Placebo in Acute Ischemic Stroke, sponsored by Takeda. Recruiting at 60 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 480 studies in Ischemic Stroke with a site in United States — 122 open to participants now, 146 under way, 13 of them phase 3. Ischemic Stroke · United States.

Planned enrollment
93rd of 364
222 · median 66
Started
2026
with 35 others
Phase 2
71 of 480
8 open now
Primary completion
2027-12
later than 84 of 145 live
Registered
456th of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 93rd largest by planned enrollment of the 364 interventional ones that give a count, is one of 36 that started in 2026, is one of 71 in phase 2, reaches primary completion later than 84 of the 145 other live ones, and was the 456th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

122 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

116 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

Acute ischemic stroke (AIS) is a medical emergency that happens because of a sudden stop of blood flow to a part of the brain. This happens when a blood clot forms within the vessel (known as thrombotic occlusion) or a clot originating from somewhere else blocks a blood vessel (known as embolic occlusion). Strokes can cause serious health problems, death, and affect one's quality of life. To reduce long-term damage, it is important to restore blood flow to the brain as soon as possible.

The main aim of this study is to check how safe TAK-755 is, and how well adults with AIS tolerate it. Other aims are to check how well TAK-755 helps participants to manage their everyday activities and to understand whether it helps reduce the seriousness of their stroke symptoms when compared to placebo. A placebo looks like TAK-755, but does not have any medicine in it, to make sure participants do not know which treatment they are taking.

The participants will receive TAK-755 or placebo once; afterwards, their health will be monitored for about 3 months (90 days). All participants, regardless of their assignment to either TAK-755 or placebo, will receive the usual treatment for AIS as per the hospital's normal practice.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

:

  1. The participant or legally authorized representative has provided informed consent or deferred consent eligibility confirmed before the initiation of any trial procedures.

    Age:

  2. greater than and equal to (>=) 18 years of age, inclusive, at the time of signing the Informed Consent Form (ICF) or confirmation of deferred consent eligibility.

    Clinical Characteristics:

  3. Clinical diagnosis of AIS.
  4. Onset of stroke symptoms within 24 hours of randomization. Wake-up strokes may be included if Last Known Well is within 24 hours of randomization; time of onset will be considered the time of Last Known Well.
  5. National Institutes of Health Stroke Scale score of 5 to 25, indicating moderate to severe stroke. Participants with an NIHSS score of 5 are eligible only if at least 1 predefined disabling neurological deficit is present, as defined by one or more of the following

    NIHSS criteria:

    • Complete hemianopia (NIHSS visual score >=2).
    • Aphasia impairing meaningful communication (NIHSS language score >=2).
    • Motor deficit with inability to sustain effort against gravity (NIHSS left or right motor arm or leg score >=2).
  6. Estimated Modified Rankin Scale score less than (\<) 2 prior to AIS presentation, signifying no significant disability.
  7. Persistent neurological signs and symptoms consistent with unilateral supratentorial circulation stroke.

    Imaging:

  8. Evidence of causative AIS occlusions affecting supratentorial circulation on imaging (intracranial internal carotid artery [ICA], middle cerebral artery [MCA; M1 - M4], anterior cerebral artery [ACA; A1 - A3], posterior cerebral artery [PCA; P1 - P3]).
  9. Evidence of salvageable brain tissue on CT or MR imaging.

Exclusion criteria

Exclusion Criteria:

Medical History:

  1. Weight >130 kilograms (kg) or \<40 kg.
  2. History of severe traumatic brain injury in the past 90 days.
  3. History of intracranial hemorrhage.
  4. History of intracranial neoplasm except for small meningioma.
  5. History of prior stroke in the past 90 days.
  6. History of intracranial or intraspinal surgery within the past 90 days.
  7. Major surgery or severe trauma in the past 14 days.
  8. History of cerebral amyloid angiopathy.
  9. Recent history of active systemic within the last 5 years, except for locally excised basal cell or squamous cell skin carcinoma with clear margins.
  10. Diagnosis of serious, advanced, or terminal illness with anticipated of less than 1 year.
  11. Participation in other interventional clinical trials within the previous 90 days.
  12. Known life-threatening reaction to TAK-755 or its components.
  13. Any prior administration of TAK-755.
  14. Administration of caplacizumab in the past 30 days.
  15. Administration of von Willebrand factor-containing products in the past 14 days.
  16. Baseline conditions (prior to the index AIS event) that prevent an understanding of the nature, scope, and possible consequences of the trial, in the judgment of the investigator.

    Current Stroke Management:

  17. Any prior administration (intravenous or intra-arterial) of alteplase or tenecteplase for the index AIS event, as well as any prior administration of prourokinase or reteplase for the index AIS event in countries where approved.
  18. Eligible for administration of intravenous thrombolysis (alteplase or tenecteplase, as well as prourokinase or reteplase in countries where approved) for the index AIS event, based on the site's standard clinical guidelines and direct availability.
  19. Intent to proceed with endovascular thrombectomy (EVT) for the index AIS event based on eligibility and direct availability.
  20. Seizure at time of index AIS event onset, only if it precludes accurate assessment of baseline NIHSS.
  21. Persistent blood pressure elevation (systolic >=185 millimeters of mercury [mmHg] or diastolic >=110 mm Hg) prior to randomization.
  22. Blood glucose \<50 milligrams per deciliter (mg/dL) or >400 mg/dL.

    Current Medical Conditions:

  23. Active, uncontrolled bleeding.
  24. Bleeding diathesis or any other conditions that would pose significant bleeding risk.
  25. Inability to undergo MRI or CT.
  26. Chronic causative intracranial occlusion.
  27. Causative total occlusion of the extracranial ICA.
  28. Evidence of septic emboli or bacterial endocarditis.
  29. Another concomitant disease that may pose additional risks for the participant in the opinion of the investigator.
  30. Pregnancy, lactation, or unable to comply with methods or abstinence as specified in the protocol in the opinion of the investigator.

    Imaging:

  31. Poor quality imaging that precludes interpretation according to trial protocol.
  32. Evidence of significant intracranial mass effect or midline shift.
  33. Evidence of acute occlusion in >1 vascular territory (right/left MCA, right/left ACA, right/left PCA); multiple occlusions within the same vascular territory are allowed.
  34. Evidence of acute or chronic intracranial hemorrhage (presence of chronic cerebral microbleeds on magnetic resonance imaging [MRI]) T2*-weighted type sequence (such as gradient recalled echo [GRE] or susceptibility weighted imaging [SWI]) is not exclusionary if total \<10 and not consistent with diagnosis of cerebral amyloid angiopathy).
  35. Evidence of extensive early ischemic change estimated to be greater than one-third of the middle cerebral artery territory or evidence of well-demarcated hypoattenuation on computed tomography (CT), if performed, consistent with established infarction and judged by the investigator to correspond to the clinical symptoms of the index AIS.
  36. Evidence of intracranial tumor (except incidental, small meningioma), cerebral aneurysm, or arteriovenous malformation.

    Laboratory:

  37. count \<50,000/ cubic millimeters (mm\^3).

    Other:

  38. Identification by the investigator as being potentially unable or unwilling to cooperate with trial procedures.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
222 participants (estimated)

Study arms

  • Experimental
    Part A: TAK-755

    Participants will receive a single intravenous (IV) infusion of TAK-755 on Day 1 of Part A. All participants will be followed for up to 90 days post treatment.

    Biological: TAK-755

  • Experimental
    Part B: TAK-755

    Participants will receive a single IV infusion of TAK-755 on Day 1 of Part B. All participants will be followed for up to 90 days post treatment.

    Biological: TAK-755

  • Placebo comparator
    Part A and B: Placebo

    Participants will receive a single IV infusion of TAK-755 matching placebo on Day 1 of Parts A and B. All participants will be followed for up to 90 days post treatment.

    Other: Placebo

Interventions

  • BiologicalTAK-755

    TAK-755 IV infusion.

    Also known as: rADAMTS13

  • OtherPlacebo

    TAK-755 matching placebo IV infusion.

06

What researchers measure

Primary outcomes

  1. Part A and B: Percentage of Participants who Develop Symptomatic Intracranial Hemorrhage (sICH) as Defined by the Heidelberg Bleeding Classification System

    The Heidelberg Bleeding Classification System is used to determine whether an Intracranial Hemorrhage (ICH) is symptomatic (sICH) or asymptomatic (aICH). It uses a structured 7-step approach that integrates imaging findings with clinical deterioration. This algorithm includes anatomic description of hemorrhage, adjudication of neurological deterioration, and relatedness between ICH and clinical deterioration. Percentage of participants who develop sICH will be reported.

    Time frame: Up to 120 hours of study drug administration

Secondary outcomes

  1. Part A: Percentage of Participants With Treatment-Related and Unrelated Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of the trial intervention, whether or not the occurrence is considered related to the trial intervention. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a trial intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the trial intervention or medicinal product. An SAE is defined as any untoward medical occurrence that results in death or is life-threatening or requires inpatient hospitalization or results in significant disability/incapacity or is a congenital anomaly or meets the definitions of other medically significant events. Percentage of participants with TEAEs and SAEs will be reported.

    Time frame: From start of study drug administration up to follow-up (up to 90 days)

  2. Part A: Percentage of Participants With Severe TEAEs

    A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a trial intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the trial intervention or medicinal product. A severe TEAE is a type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Percentage of participants with severe TEAEs will be reported.

    Time frame: From start of study drug administration up to follow-up (up to 90 days)

  3. Part A: Percentage of Participants With Life-Threatening Adverse Events (AEs)

    Percentage of participants with life-threatening AEs will be reported.

    Time frame: From start of study drug administration up to follow-up (up to 90 days)

  4. Part A: Percentage of Participants With AEs of Special Interest (AESIs)

    AESIs include sICH, treatment-related aICH, treatment-related extracranial bleeding SAEs, and recurrent AIS. Percentage of participants with AESIs will be reported.

    Time frame: From start of study drug administration up to 168 hours

  5. Part A: Percentage of Participants With Clinically Relevant Changes in Vital Signs

    Vital signs will include measurement of body temperature, respiratory rate, blood pressure and pulse rate. Any clinically relevant changes in vital signs will be determined at the investigator's discretion.

    Time frame: From screening up to 90 days

  6. Part A: Percentage of Participants With Clinically Relevant Changes in Clinical Chemistry and Hematology

    Laboratory parameters will include clinical chemistry and hematology. Any clinically relevant changes in laboratory values will be determined at the investigator's discretion.

    Time frame: From screening up to 90 days

  7. Part A: Number of Participants With Treatment-induced Binding Antibodies to ADAMTS13

    As per planned analysis, blood sample will be collected to monitor the development of binding antibodies to ADAMTS13.

    Time frame: From Day 30 to Day 90

  8. Part A: Number of Participants With Treatment-induced Neutralizing Antibodies to ADAMTS13

    As per planned analysis, blood sample will be collected to monitor the development of neutralizing antibodies to ADAMTS13.

    Time frame: From Day 30 to Day 90

  9. Part A: Percentage of Participants With All-cause Mortality

    Percentage of participants who died during the entire study period will be reported.

    Time frame: From start of study drug administration up to follow-up (up to 90 days)

  10. Part A and B: Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-1

    The mRS assessment will be used to grade the level of functional independence of participants following a stroke. It is a single-item, global outcome rating scale that categorizes functional independence based on pre-stroke activities, with seven grades representing no (0), no significant (1), slight (2), moderate (3), moderately severe (4), severe (5) disability and death (6). Lower scores indicate better functional outcome. Percentage of participants with mRS of 0-1 will be reported.

    Time frame: At Day 90

  11. Part A and B: Percentage of Participants With mRS Score of 0-2

    The mRS assessment will be used to grade the level of functional independence of participants following a stroke. It is a single-item, global outcome rating scale that categorizes functional independence based on pre-stroke activities, with seven grades representing no (0), no significant (1), slight (2), moderate (3), moderately severe (4), severe (5) disability and death (6). Lower scores indicate better functional outcome. Percentage of participants with mRS of 0-2 will be reported.

    Time frame: At Day 90

  12. Part A and B: Ordinal Distribution of mRS at Day 90

    The mRS assessment will be used to grade the level of functional independence of participants following a stroke. It is a single-item, global outcome rating scale that categorizes functional independence based on pre-stroke activities, with seven grades representing no (0), no significant (1), slight (2), moderate (3), moderately severe (4), severe (5) disability and death (6). Lower scores indicate better functional outcome.

    Time frame: At Day 90

  13. Part A and B: Change From Baseline in National Institutes of Health Stroke Scale (NIHSS) Score at 24 Hours

    The NIHSS is a tool to objectively quantify the impairment caused by a stroke. NIHSS assessment is a 15-item impairment scale assessing level of consciousness, extraocular movements, visual fields, facial muscle function, extremity strength, sensory function, coordination (ataxia), language (aphasia), speech (dysarthria), and hemi-inattention (neglect). The total score ranges from 0 to 42 where higher scores indicate greater impairment. A negative change from Baseline indicates improvement.

    Time frame: Baseline up to 24 hours

  14. Part A and B: Percentage of Participants With Recanalization According to Arterial Occlusive Lesion (AOL) Score of 3

    The AOL scale score is a measure of recanalization and ranges from 0 to 3. The grading scale specifically measures the degree of recanalization at the defined target or causative occlusion. A score of 0 is defined as complete occlusion of the target artery. Scores of 1 and 2 account for partial recanalization, with a score of 1 indicating no distal flow while a score of 2 indicates any distal flow. A score of 3 is defined as complete recanalization with any distal flow. Percentage of participants with AOL Score of 3 will be reported.

    Time frame: At 24 Hours

  15. Part A and B: Percentage of Participants With Reperfusion

    Percentage of participants with reperfusion, defined as \>90 percent (%) reduction from baseline in volume of tissue with time-to maximum (Tmax) \>6 seconds on perfusion imaging will be reported.

    Time frame: At 24 Hours

  16. Part A and B: Final Infarct Volume

    Final infarct volume at 72 hours or hospital discharge (if earlier than 72 hours) will be reported.

    Time frame: At 72 hours or earlier at hospital discharge

07

Study locations

13 of 60 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's planned 18 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2026
First posted
Feb 6, 2026
StartActual
May 17, 2026
Primary completionEst.
Dec 6, 2027
CompletionEst.
Dec 6, 2027
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07392450
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
May 17, 2026
Primary completion
Dec 6, 2027 (estimated)
Completion
Dec 6, 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apadamtase alfa

Start the discussion